

presentations are permitted. Comments should identify the individual's name, address, email, telephone number, professional or organization affiliation, background or area of expertise (e.g., parent, family member, researcher, clinician, public health, etc.), and the topic/subject matter. Oral comments must be presented in-person and not via phone/webinar.

Individuals who plan to attend and need special assistance or another reasonable accommodation should notify David S. de la Cruz at the address and phone number listed above at least 10 days prior to the meeting. Since this meeting occurs in a federal government building, attendees must go through a security check to enter the building. Non-U.S. Citizen attendees must notify HRSA of their planned attendance at least 10 business days prior to the meeting in order to facilitate their entry into the building. All attendees are required to present government-issued identification prior to entry.

**Amy P. McNulty,**

*Acting Director, Division of the Executive Secretariat.*

[FR Doc. 2018-25105 Filed 11-16-18; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Notice of Interest Rate on Overdue Debts

Section 30.18 of the Department of Health and Human Services' claims collection regulations (45 CFR part 30) provides that the Secretary shall charge an annual rate of interest, which is determined and fixed by the Secretary of the Treasury after considering private consumer rates of interest on the date that the Department of Health and Human Services becomes entitled to recovery. The rate cannot be lower than the Department of Treasury's current value of funds rate or the applicable rate determined from the "Schedule of Certified Interest Rates with Range of Maturities" unless the Secretary waives interest in whole or part, or a different rate is prescribed by statute, contract, or repayment agreement. The Secretary of the Treasury may revise this rate quarterly. The Department of Health and Human Services publishes this rate in the **Federal Register**.

The current rate of 10 $\frac{1}{8}$ %, as fixed by the Secretary of the Treasury, is certified for the quarter ended September 30, 2018. This rate is based on the Interest Rates for Specific Legislation, "National

Health Services Corps Scholarship Program (42 U.S.C. 254o(b)(1)(A))" and "National Research Service Award Program (42 U.S.C. 288(c)(4)(B))." This interest rate will be applied to overdue debt until the Department of Health and Human Services publishes a revision.

Dated: October 10, 2018.

**David C. Horn,**

*Director, Office of Financial Policy and Reporting.*

[FR Doc. 2018-25204 Filed 11-16-18; 8:45 am]

**BILLING CODE 4150-04-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Activities Deemed Not To Be Research: Public Health Surveillance, 2018 Requirements

**AGENCY:** The Office for Human Research Protections, Office of the Assistant Secretary for Health, Office of the Secretary, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Office for Human Research Protections (OHRP), Office of the Assistant Secretary for Health, is announcing the availability of a draft guidance document entitled, "Activities Deemed Not to Be Research: Public Health Surveillance, 2018 Requirements."

**DATES:** Submit written comments by December 19, 2018.

**ADDRESSES:** Submit written requests for a single copy of the draft guidance document entitled "Activities Deemed Not to Be Research: Public Health Surveillance, 2018 Requirements," to the Division of Policy and Assurances, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852. Send one self-addressed adhesive label to assist that office in processing your request, or fax your request to 240-453-6909. See the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the draft guidance documents.

You may submit comments identified by docket ID number HHS-OS-OPHS-2018-0015 (Activities Deemed Not to Be Research: Public Health Surveillance, 2018 Requirements), by one of the following methods:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Enter the docket ID number and click on "Search." On the next page, click the "Comment Now" action and follow the instructions.

- *Mail/Hand delivery/Courier [For paper, disk, or CD-ROM submissions]:* Irene Stith-Coleman, Ph.D., Office for

Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852.

Comments received, including any personal information, will be posted without change to <http://www.regulations.gov>.

#### **FOR FURTHER INFORMATION CONTACT:**

Irene Stith-Coleman, Ph.D., Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852, 240-453-6900; email [Irene.Stith-Coleman@hhs.gov](mailto:Irene.Stith-Coleman@hhs.gov).

#### **SUPPLEMENTARY INFORMATION:**

### I. Background

#### A. Overview

OHRP, Office of the Assistant Secretary for Health, is announcing the availability of a draft guidance document entitled "Activities Deemed Not to Be Research: Public Health Surveillance, 2018 Requirements." This guidance document applies to activities that are conducted or supported by HHS. It is intended to help entities determine whether a planned activity constitutes a public health surveillance activity deemed not to be research under the 2018 Requirements (the revised subpart A of 45 CFR part 46, effective July 19, 2018). The draft guidance document, when finalized, will represent OHRP's current thinking on this topic. OHRP obtained input from HHS agencies and the Common Rule departments and agencies in developing the draft guidance document.

### II. Electronic Access

Persons with access may obtain the draft guidance documents on OHRP's website at <https://www.hhs.gov/ohrp/regulations-and-policy/requests-for-comments/index.html>.

Dated: November 8, 2018.

**Julie Kaneshiro,**

*Deputy Director, Office for Human Research Protections.*

[FR Doc. 2018-25202 Filed 11-16-18; 8:45 am]

**BILLING CODE 4150-36-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Biodefense Science Board Public Teleconference

**AGENCY:** Office of the Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human

Services is hereby giving notice that the National Biodefense Science Board (NBSB) will hold a public teleconference on December 13, 2018.

**DATES:** The NBSB Public Teleconference is December 13, 2018, from 2:00 p.m. to 4:00 p.m. Eastern Standard Time (EST).

**ADDRESSES:** We encourage members of the public to attend the public meetings. To register, send an email to [nbsb@hhs.gov](mailto:nbsb@hhs.gov) with "NBSB Registration" in the subject line. Submit your comments to [nbsb@hhs.gov](mailto:nbsb@hhs.gov), the NBSB Contact Form located at <https://www.phe.gov/Preparedness/legal/boards/nbsb/Pages/RFNBSBComments.aspx>. For additional information, visit the NBSB website located at <https://www.phe.gov/nbsb>.

**SUPPLEMENTARY INFORMATION:** The NBSB is authorized under Section 319M of the Public PHS Act (42 U.S.C. 247d-7f), as added by Section 402 of the Pandemic and All-Hazards Preparedness Act of 2006 and amended by Section 404 of the Pandemic and All-Hazards Preparedness Reauthorization Act. The Board is governed by the Federal Advisory Committee Act (5 U.S.C. App.), which sets forth standards for the formation and use of advisory committees. The NBSB provides expert advice and guidance on scientific, technical, and other matters of special interest to the Department regarding current and future chemical, biological, nuclear, and radiological agents, whether naturally occurring, accidental, or deliberate.

**Background:** The December 13, 2018, NBSB public teleconference is dedicated to the discussion of recommendations on two topics: (1) Strategic improvements to the National Disaster Medical System (NDMS) and (2) implementation of the National Biodefense Strategy. We will post modifications to the agenda on the NBSB meeting website, which is located at <https://www.phe.gov/nbsb>.

**Availability of Materials:** We will post all teleconference materials prior to the teleconference on December 13, 2018, at the website located at <https://www.phe.gov/nbsb>.

**Procedures for Providing Public Input:** Members of the public may attend the public teleconference via a toll-free call-in phone number, which is available on the NBSB website at <https://www.phe.gov/nbsb>.

We encourage members of the public to provide written comments that are relevant to the NBSB public teleconference prior to December 13, 2018. Send written comments by email to [nbsb@hhs.gov](mailto:nbsb@hhs.gov) with "NBSB Public Comment" in the subject line. The

NBSB Chair will respond to comments received by December 12, 2018, during the public teleconference.

Dated: November 8, 2018.

**Robert P. Kadlec,**

*Assistant Secretary for Preparedness and Response.*

[FR Doc. 2018-25131 Filed 11-16-18; 8:45 am]

**BILLING CODE 4150-28-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID 2018 Omnibus BAA (HHS-NIH-NIAID-BAA2018) Research Area 001: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases.

**Date:** December 11-12, 2018.

**Time:** 10:00 a.m. to 4:00 p.m.

**Agenda:** To review and evaluate contract proposals.

**Place:** National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

**Contact Person:** Kumud K. Singh, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC-9823, Rockville, MD 20852, 301-761-7830, [kumud.singh@nih.gov](mailto:kumud.singh@nih.gov).

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID Investigator Initiated Program Project Applications (P01).

**Date:** December 11, 2018.

**Time:** 10:00 a.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

**Contact Person:** Priti Mehrotra, Ph.D., Chief, Immunology Review Branch, Scientific

Review Program, Division of Extramural Activities, Room #3G40, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-7616, 240-669-5066, [pmehrotra@niaid.nih.gov](mailto:pmehrotra@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 14, 2018.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2018-25191 Filed 11-16-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Cancers

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to ElevateBio. ("Elevate"), located in Cambridge, MA.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 4, 2018 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Jim Knabb, Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530, MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-9702; Telephone: (240)-276-7856; Facsimile: (240)-276-5504; Email: [jim.knabb@nih.gov](mailto:jim.knabb@nih.gov).

**SUPPLEMENTARY INFORMATION:**